Core Viewpoint - The stock of Giant Bio (02367) has rebounded over 6%, currently trading at 40.1 HKD with a transaction volume of 411 million HKD, following the approval of its first medical aesthetic product, a type I collagen freeze-dried fiber for facial dermal filling [1] Group 1: Product Development - Giant Bio's first medical aesthetic product, a type I collagen freeze-dried fiber, has been approved for use in correcting dynamic facial wrinkles, including frown lines, forehead lines, and crow's feet [1] - The company is currently developing three additional medical aesthetic products, which include facial hydration, neck wrinkle treatments, and volumizing fillers [1] Group 2: Market Analysis - According to Guotai Junan Securities, the main brand, Kefu Mei, has seen a decline in its Double Eleven ranking due to public sentiment, product structure, and competition, which may lead to temporary pressure on the skincare business [1] - Despite the challenges, the company has strong brand equity and operational foundations, with a focus on future channel adjustments and new product launches [1] Group 3: Growth Potential - The newly approved collagen product is expected to contribute to a second growth curve for the company, given its anti-aging and repair benefits, along with a solid recognition of its ingredients [1] - The company has a foundational presence in the medical aesthetic channel, which positions it well for the product's market introduction [1]
巨子生物反弹逾6% 重组胶原医美产品获批 后续有望贡献第二增长曲线